The 'cutting edge' of gene therapy... literally - Zinc-finger exercises

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The traditional gene-therapy approach relies on the delivery of a therapeutic transgene into a cell, typically to compensate for a gene that is not functional owing to a genetic defect. But why not just correct the genetic defects directly? The answer used to be that there was no methodology for making precise genetic modifications in a highly efficient manner. That is changing now. Over the last decade, researchers have devised a way to stimulate the natural DNA-repair mechanisms of the cell to occur at any desired site in the genome. The enabling technological advance has been the development of programmable nucleases, which use re-engineered ZF (zinc-finger) DNA-binding domains to cut the DNA in a living cell at a precise user-defined location. These methods have been shown to produce genetic modifications at frequencies of >1 correct event per ten treated cells, representing a 100000-fold stimulation of targeted gene repair. The first Phase I clinical trial of a therapeutic ZFN (zinc-finger nuclease) is scheduled for 2008.

Original languageEnglish (US)
Pages (from-to)10-13
Number of pages4
JournalBiochemist
Volume30
Issue number3
StatePublished - Jun 2008

Fingerprint

Gene therapy
Zinc Fingers
Genetic Therapy
Zinc
Genes
DNA
Repair
Cells
Targeted Gene Repair
Defects
Clinical Trials, Phase I
Transgenes
DNA Repair
Research Personnel
Genome
Therapeutics

Keywords

  • Engineered zinc finger
  • Gene repair
  • Gene therapy
  • HIV
  • Homologous recombination
  • Mutation correction
  • Protein engineering
  • Zinc-finger nuclease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The 'cutting edge' of gene therapy... literally - Zinc-finger exercises. / Segal, David.

In: Biochemist, Vol. 30, No. 3, 06.2008, p. 10-13.

Research output: Contribution to journalArticle

@article{ed76d635674246f4bfb310715592435a,
title = "The 'cutting edge' of gene therapy... literally - Zinc-finger exercises",
abstract = "The traditional gene-therapy approach relies on the delivery of a therapeutic transgene into a cell, typically to compensate for a gene that is not functional owing to a genetic defect. But why not just correct the genetic defects directly? The answer used to be that there was no methodology for making precise genetic modifications in a highly efficient manner. That is changing now. Over the last decade, researchers have devised a way to stimulate the natural DNA-repair mechanisms of the cell to occur at any desired site in the genome. The enabling technological advance has been the development of programmable nucleases, which use re-engineered ZF (zinc-finger) DNA-binding domains to cut the DNA in a living cell at a precise user-defined location. These methods have been shown to produce genetic modifications at frequencies of >1 correct event per ten treated cells, representing a 100000-fold stimulation of targeted gene repair. The first Phase I clinical trial of a therapeutic ZFN (zinc-finger nuclease) is scheduled for 2008.",
keywords = "Engineered zinc finger, Gene repair, Gene therapy, HIV, Homologous recombination, Mutation correction, Protein engineering, Zinc-finger nuclease",
author = "David Segal",
year = "2008",
month = "6",
language = "English (US)",
volume = "30",
pages = "10--13",
journal = "Biochemist",
issn = "0954-982X",
publisher = "Portland Press Ltd.",
number = "3",

}

TY - JOUR

T1 - The 'cutting edge' of gene therapy... literally - Zinc-finger exercises

AU - Segal, David

PY - 2008/6

Y1 - 2008/6

N2 - The traditional gene-therapy approach relies on the delivery of a therapeutic transgene into a cell, typically to compensate for a gene that is not functional owing to a genetic defect. But why not just correct the genetic defects directly? The answer used to be that there was no methodology for making precise genetic modifications in a highly efficient manner. That is changing now. Over the last decade, researchers have devised a way to stimulate the natural DNA-repair mechanisms of the cell to occur at any desired site in the genome. The enabling technological advance has been the development of programmable nucleases, which use re-engineered ZF (zinc-finger) DNA-binding domains to cut the DNA in a living cell at a precise user-defined location. These methods have been shown to produce genetic modifications at frequencies of >1 correct event per ten treated cells, representing a 100000-fold stimulation of targeted gene repair. The first Phase I clinical trial of a therapeutic ZFN (zinc-finger nuclease) is scheduled for 2008.

AB - The traditional gene-therapy approach relies on the delivery of a therapeutic transgene into a cell, typically to compensate for a gene that is not functional owing to a genetic defect. But why not just correct the genetic defects directly? The answer used to be that there was no methodology for making precise genetic modifications in a highly efficient manner. That is changing now. Over the last decade, researchers have devised a way to stimulate the natural DNA-repair mechanisms of the cell to occur at any desired site in the genome. The enabling technological advance has been the development of programmable nucleases, which use re-engineered ZF (zinc-finger) DNA-binding domains to cut the DNA in a living cell at a precise user-defined location. These methods have been shown to produce genetic modifications at frequencies of >1 correct event per ten treated cells, representing a 100000-fold stimulation of targeted gene repair. The first Phase I clinical trial of a therapeutic ZFN (zinc-finger nuclease) is scheduled for 2008.

KW - Engineered zinc finger

KW - Gene repair

KW - Gene therapy

KW - HIV

KW - Homologous recombination

KW - Mutation correction

KW - Protein engineering

KW - Zinc-finger nuclease

UR - http://www.scopus.com/inward/record.url?scp=45349107029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45349107029&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:45349107029

VL - 30

SP - 10

EP - 13

JO - Biochemist

JF - Biochemist

SN - 0954-982X

IS - 3

ER -